Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses

1. A method of inhibiting proliferation of a cell comprising contacting the cell with an amount of (1R,2R,3S,4S)—N4-(3-aminocarbonylbicyclo[2.2.1]hept-5-ene-2-yl)-5-fluoro-N2-[3-methyl-4-(4-methylpiperazin-1-yl)]phenyl-2,4-pyrimidinediamine effective to inhibit its proliferation.

2. The method of claim 1 in which the cell is a tumor cell.

3. The method of claim 2 in which the tumor cell is a lung, colon, breast, gastric, ovarian, cervical, melanoma, renal, prostate, leukemia, lymphoma, neuroblastoma, pancreatic, bladder, or hepatic tumor cell.

4. A method of inhibiting an activity of an Aurora kinase comprising contacting the Aurora kinase with an amount of (1R,2R,3S,4S)—N4-(3-aminocarbonylbicyclo[2.2.1]hept-5-ene-2-yl)-5-fluoro-N2-[3-methyl-4-(4-methylpiperazin-1-yl)]phenyl-2,4-pyrimidinediamine effective to inhibit its activity.

5. The method of claim 4 which is carried out in vitro with an isolated or partially isolated Aurora kinase.

6. The method of claim 4 which is carried out in vitro with a cell expressing an Aurora kinase.

7. A method of inhibiting an Aurora kinase-mediated process comprising contacting a cell expressing an Aurora kinase with an amount of (1R,2R,3S,4S)—N4-(3-aminocarbonylbicyclo[2.2.1]hept-5-ene-2-yl)-5-fluoro-N2-[3-methyl-4-(4-methylpiperazin-1-yl)]phenyl-2,4-pyrimidinediamine effective to inhibit the Aurora kinase-mediated process.

8. The method of claim 7 in which the Aurora kinase-mediated process inhibited is mitosis.

9. The method of claim 7 in which the cell is a tumor cell.

10. The method of claim 7 in which the cell is contacted with a concentration of the compound that is equal to or greater than its IC 50 as measured in an in vitro assay.

11. A method of treating an Aurora kinase-mediated disease, comprising administering to a subject in need thereof an amount of (1R,2R,3S,4S)—N4-(3-aminocarbonylbicyclo[2.2.1]hept-5-ene-2-yl)-5-fluoro-N2-[3-methyl-4-(4-methylpiperazin-1-yl)]phenyl-2,4-pyrimidinediamine effective to treat the disease.

12. The method of claim 11 in which the Aurora kinase-mediated disease is a proliferative disease.

13. The method of claim 12 in which the proliferative disease is cancer.

14. The method of claim 13 in which the cancer is a metastatic tumor.

15. The method of claim 14 in which the cancer is selected from lung cancer, breast cancer, gastric cancer, ovarian cancer, cervical cancer, melanoma, renal cancer, prostate cancer, leukemia, lymphoma, neuroblastoma, pancreatic cancer, bladder cancer, and liver cancer.

16. The method of claim 11 in which the compound is administered in the form of a pharmaceutical composition.

17. The method of claim 11 in which the compound is administered orally.

18. The method of claim 11 in which the compound is administered intravenously.

19. The method of claim 11 in which the subject is a human.

20. The method of claim 11 in which the compound is administered in an amount effective to achieve a serum concentration that is at or above the IC 50 of the compound, as measured in an in vitro assay.

21. The method of claim 11 in which the proliferative disease is a cancer that is lung carcinoma, pancreatic adenocarcinoma, ovarian adenocarcinoma, colorectal adenocarcinoma, prostate carcinoma, non-small cell lung carcinoma, cervical adenocarcinoma, promyeloblast promyelocytic leukemia, bone marrow chronic myelogenous leukemia, lymphocytic leukemia, pancreatic carcinoma, T lymphoblast acute lymphoblastic leukemia, prostate adenocarcinoma, pancreatic carcinoma, monocyte acute monocytic leukemia, ovarian clear cell carcinoma, bone osteosarcoma, or histiocytic lymphoma.

22. The method of claim 11 in which the proliferative disease is a cancer that is colorectal adenocarcinoma, lung carcinoma, or pancreatic carcinoma.

23. The method of claim 11 in which the proliferative disease colon cancer.